title: Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
abstract: Although the combination of lenalidomide and dexamethasone is effective therapy for patients with relapsed/refractory multiple myeloma, the influence of high-risk cytogenetic abnormalities on outcomes is unknown. This subanalysis of a large, open-label study investigated the effects of the most common unfavorable cytogenetic abnormalities detected by fluorescence in situ hybridization, del(13q), t(4;14), and del(17p13), in 130 evaluable patients treated with this regimen. Whereas patients with either del(13q) or t(4;14) experienced a median time to progression and overall survival comparable with those without these cytogenetic abnormalities, patients with del(17p13) had a significantly worse outcome, with a median time to progression of 2.22 months (hazard ratio, 2.82; P < .001) and median overall survival of 4.67 months (hazard ratio, 3.23; P < .001). Improved therapeutic strategies are required for this subgroup of patients. This study was registered at www.ClinicalTrials.gov as #NCT00179647.
authors.affiliation: Division of Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: Donna
authors.initials: D
authors.lastname: Reece
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Song
authors.forename: Tommy
authors.initials: T
authors.lastname: Fu
authors.forename: Birgitte
authors.initials: B
authors.lastname: Roland
authors.forename: Hong
authors.initials: H
authors.lastname: Chang
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Horsman
authors.forename: Adnan
authors.initials: A
authors.lastname: Mansoor
authors.forename: Christine
authors.initials: C
authors.lastname: Chen
authors.forename: Esther
authors.initials: E
authors.lastname: Masih-Khan
authors.forename: Young
authors.initials: Y
authors.lastname: Trieu
authors.forename: Helene
authors.initials: H
authors.lastname: Bruyere
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Stewart
authors.forename: Nizar J
authors.initials: NJ
authors.lastname: Bahlis